282 related articles for article (PubMed ID: 34993574)
1. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
Huang F; Brezden-Masley C; Chan KKW; Barfett JJ; Kirpalani A; Deva DP; Jimenez-Juan L; Barthur A; Song L; Chacko B; Ng MY; Connelly K; Wong KCK; Yan AT
Eur Radiol; 2022 Jun; 32(6):4234-4242. PubMed ID: 34993574
[TBL] [Abstract][Full Text] [Related]
2. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study.
Shi Y; Qiu Z; Yu J; Li Z; Hua S; Chen Y; Chen X; Shen K; Jin W
BMC Cancer; 2023 Jul; 23(1):615. PubMed ID: 37400804
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
4. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
6. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
8. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
9. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Chow CM; Thavendiranathan D; Haq R; Barfett JJ; Petrella TM; Connelly KA; Yan AT
Int J Cardiol; 2018 Jun; 261():228-233. PubMed ID: 29555336
[TBL] [Abstract][Full Text] [Related]
10. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
12. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
13. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
Song L; Brezden-Masley C; Ramanan V; Ghugre N; Barfett JJ; Chan KKW; Haq R; Petrella T; Dhir V; Jimenez-Juan L; Chacko BR; Kotha V; Connelly KA; Yan AT
Am J Cardiol; 2019 Apr; 123(7):1173-1179. PubMed ID: 30683420
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
15. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
16. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
17. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
18. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
Bouwer NI; Liesting C; Kofflard MJM; Brugts JJ; Kock MCJ; Kitzen JJEM; Levin MD; Boersma E
Cardiovasc Ultrasound; 2021 Nov; 19(1):35. PubMed ID: 34753503
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
Glen C; Morrow A; Roditi G; Hopkins T; Macpherson I; Stewart P; Petrie MC; Berry C; Epstein F; Lang NN; Mangion K
Heart; 2024 Apr; 110(9):650-656. PubMed ID: 38103912
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
